Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hans-Peter Guler"'
Autor:
Xin Li, Jianke Li, Richard Molenkamp, Andre van Vliet, Christine J. Weegink, Daphne M. Hotho, Hans-Peter Guler, Joep de Bruijne, Harry L.A. Janssen, A. Marie O'Farrell, Teresa Boyea, Michele Bracken, Hendrik W. Reesink, Robert J. de Knegt, Jeroen van de Wetering de Rooij, Janke Schinkel, David Campbell
Publikováno v:
Antiviral therapy, 17(2), 365-375. International Medical Press Ltd
Antiviral Therapy, 17(2), 365-375. International Medical Press Ltd
Antiviral Therapy, 17(2), 365-375. International Medical Press Ltd
Background PHX1766 is a novel HCV NS3/4 protease inhibitor with robust potency and high selectivity in replicon studies (50% maximal effective concentration 8 nM). Two clinical trials investigated the safety, tolerability, pharmacokinetics and antivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e4536e7309611d74c0d1d4394da0c6d
https://pure.eur.nl/en/publications/30b87d3c-5c66-4068-9ee3-f0fb85cebe5a
https://pure.eur.nl/en/publications/30b87d3c-5c66-4068-9ee3-f0fb85cebe5a
Autor:
Kirsti Klemm, Sherwyn Schwartz, Julie M. Cherrington, Hans-Peter Guler, Jianke Li, Teresa Boyea, A. Marie O'Farrell
Publikováno v:
Current Medical Research and Opinion. 26:2003-2010
Dutogliptin is a novel, orally available, potent, and selective DPP4 inhibitor that improves glycemic control in type 2 diabetic patients. The objective of this study was to evaluate the potential pharmacokinetic and pharmacodynamic interactions, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb9ce6200958727f75ccd1f0adf9ae1
https://doi.org/10.1185/03007995.2010.491266
https://doi.org/10.1185/03007995.2010.491266
Autor:
Xinqiang Li, Jianke Li, Khalid Abou Farha, David Campbell, A. Marie O'Farrell, Julie M. Cherrington, Denise Hanway, Hans-Peter Guler, Andre van Vliet
Publikováno v:
Clinical Therapeutics. 29:1692-1705
Background: PHX1149 is a dipeptidyl peptidase-4 (DPP4) inhibitor that is currently in clinical development for the treatment of type 2 diabetes mellitus. PHX1149 is a small (molecular weight=241.16 Da), highly water-soluble (>2 g/mL), orally active m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d98fbf11f0443621581c8a032c0a6219
https://doi.org/10.1016/j.clinthera.2007.08.005
https://doi.org/10.1016/j.clinthera.2007.08.005
Autor:
Marilyn Pike, Brian Myers, Timothy E Albertson, Warren R. Summer, Wade McKeown, Raymond L. Hintz, Mark A. Munger, Pamela A. Lipsett, Joseph P. Minei, Michael H. O'Shea, Roger Kaiser, Ernest Benjamin, Robert P. Baughman, Michael Metzler, Hank Simms, Hans Peter Guler, Kenneth E. Wood, Kathrine Haenftling, Marilyn Haupt, David G. Warnock, William Capra, Raimund Hirschberg, John D. Conger, Michael J. Murray, Stephen F. Lowry, Joel D. Kopple, Gary P. Zaloga
Publikováno v:
Kidney International. 55(6):2423-2432
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.BackgroundPatients with acute renal failure (ARF) have high morbidity and mortality rates, particularly if they have serious comorbid co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6223eda95825a69049ac08803be157b6
Autor:
Gretchen Carrougher, William F. McManus, Loring W. Rue, William G. Cioffi, Dennis C. Gore, Hans Peter Guler, Basil A. Pruitt
Publikováno v:
Annals of Surgery. 220:310-319
OBJECTIVE: The effect of insulin-like growth factor-1 (IGF-1) on energy expenditure and protein and glucose metabolism in a group of patients with thermal injury was determined. SUMMARY BACKGROUND DATA: Accelerated protein catabolism is a constant fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5ccaaf7fb758496619d4d5632b03f3
https://doi.org/10.1097/00000658-199409000-00007
https://doi.org/10.1097/00000658-199409000-00007
Autor:
Barbara J Radnik, Nancy J Turman, Nabeel Jabri, Mark S. Kipnes, Sherwyn Schwartz, Don S. Schalch, Victoria S Marcsisin, Jerome S. Fischer, Hans-Peter Guler
Publikováno v:
Diabetes. 43:369-374
Data from studies in diabetic rodents and evidence from clinical situations of severe resistance to insulin suggest that insulin-like growth factor I (IGF-I) is able to at least partly overcome insulin resistance. To assess the efficacy of recombinan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a41b4cb870ad17d71128275cf53853b
https://doi.org/10.2337/diab.43.3.369
https://doi.org/10.2337/diab.43.3.369
Publikováno v:
Trends in Endocrinology & Metabolism. 1:254-260
Human recombinant insulinlike growth factor I is a promising therapeutic agent for diseases characterized by relative insulin resistance, e.g., diabetes mellitus, obesity, and hypertriglyceridemia, since it suppresses growth hormone, insulin, C-pepti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1723bdeb72a61a13d12aa502187e8e6
https://doi.org/10.1016/1043-2760(90)90006-o
https://doi.org/10.1016/1043-2760(90)90006-o
Autor:
Vivian A. John, David M. Capuzzi, Steven D. Saris, Anthony J. Piraino, John J. Seaman, William R. Good, Hans-Peter Guler, John M. Morgan
Publikováno v:
Journal of clinical pharmacology. 33(4)
Recombinant human insulin-like growth factor-I (rhIGF-I) produced by expression in a yeast vector was evaluated in seven normal men to determine effects on plasma glucose and insulin levels. Each subject received an initial intravenous infusion of no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c54c99a8d0d35264c3b3a37a0e9354
https://pubmed.ncbi.nlm.nih.gov/8473552
https://pubmed.ncbi.nlm.nih.gov/8473552
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9781468459517
Two major forms of insulin-like growth factors (IGF-I and IGF-II) and their specific binding proteins have been detected in body fluids, including serum, cerebrospinal fluid, breast milk, lymph, and saliva. Extracts of almost any tissue reveal the pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55f52ed38438213657d21b55ba6c9273
https://doi.org/10.1007/978-1-4684-5949-4_9
https://doi.org/10.1007/978-1-4684-5949-4_9
Autor:
Eugene R. Heyman, Hans-Peter Guler, Stanley Heshka, Mark P. Ettinger, Catherine Vicary, Sherwyn Schwartz, Harris H. McIlwain, William G. Roberts, George A. Bray, Stuart R. Weiss, Nancy Stambler, Thomas W. Littlejohn, Steven B. Heymsfield
Publikováno v:
JAMA. 289:1826
ContextObese individuals tend to resist the weight-regulating effects of exogenously administered leptin. A genetically engineered recombinant human variant ciliary neurotrophic factor (rhvCNTF) that signals through leptinlike pathways in the hypotha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e15536ca4d47b2bce5bd231c1f8d47
https://doi.org/10.1001/jama.289.14.1826
https://doi.org/10.1001/jama.289.14.1826